Ethical considerations in clinical pharmacogenomics research

Trends in Pharmacological Sciences

Volumn 21, Issue 7, 2000, Pages 247-249

  Issa, Amalia M ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DATA BASE; DRUG DEVELOPMENT; ETHICS; FAMILY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; PHARMACOECONOMICS; PHARMACOGENOMICS; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SHORT SURVEY;

EID: 0034234719     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(00)01493-0     Document Type: Note

References (20)

1. Linder M.W.et al. Pharmacogenetics. a laboratory tool for optimizing therapeutic efficiency Clin. Chem. 43:1997;254-266.
2. Grahame-Smith D.G. How will knowledge of the human genome affect drug therapy? Br. J. Clin. Pharmacol. 47:1999;7-10.
3. Ingelman-Sundberg M.et al. Polymorphic human cytochrome P450 enzymes. an opportunity for individualized drug treatment Trends Pharmacol. Sci. 20:1999;342-349.
4. Marshall A. Getting the right drug into the right patient. Nat. Biotechnol. 15:1997;1249-1252.
5. Weijer C.W. Selecting subjects for participation in clinical research. one sphere of justice J. Med. Ethics. 25:1999;31-36.
6. Schork N.J., Weder A.B. The use of genetic information in large-scale clinical trials: applications to Alzheimer research. Alzheimer Dis. Assoc. Disord. 10:1996;22-26.
7. Smith C.K. Spectra biomedical sees future in personalized genetic profiling services. Genet. Eng. News. 17:1996;10-28.
8. Guthrie R. The introduction of newborn screening for phenylketonuria. A personal history. Eur. J. Pediatr. 155:1996;S4-S5.
9. Knoppers B.M. Towards a reconstruction of the `genetic family': new principles? Int. Digest Health Legisl. 49:1998;241-253.
10. Engelhardt H.T. The Foundations of Bioethics (2nd edn). 1996;Oxford University Press.
11. Coughlin S.S.et al. BRCA1 and BRCA2 gene mutations and risk of breast cancer. Public health perspectives. Am. J. Prev. Med. 16:1999;91-98.
12. Tang M.X.et al. Relative risk of Alzheimer's disease and age-at-onset distributions, based on APOE genotypes among elderly African Americans, Caucasians and Hispanics in New York City. Am. J. Hum. Genet. 58:1996;574-584.
13. Weijer C.W. Protecting communities in research. philosophical and pragmatic challenges Camb. Q. Healthcare Ethics. 8:1999;501-513.
14. Annas G.J. Some Choice: Law, Medicine and the Market. 1998;Oxford University Press.
15. Lapham E.V.et al. Genetic discrimination. perspectives of consumers Science. 274:1996;621-624.
16. Lemmens T., Poupak B. Genetics in life, disability and additional health insurance in Canada: a comparative legal and ethical analysis. Knoppers B.M. Socio-ethical Issues in Human Genetics. 1998;107-275 Les Èditions Yvon Blais.
17. Galton D.J., Ferns G.A.A. Genetic markers to predict polygenic disease. a new problem for social genetics Q. J. Med. 92:1999;223-232.
18. Classen D.C.et al. Adverse drug events in hospitalized patients. excessive length of stay, extra costs, and attributable mortality J. Am. Med. Assoc. 277:1997;301-306.
19. Schulman K.A., Linas B.P. Pharmacoeconomics. state of the art Annu. Rev. Pub. Health. 18:1997;529-548.
20. Persidis A. The business of pharmacogenomics. Nat. Biotechnol. 16:1998;209-210.